Madrigal pharmaceuticals enters into exclusive global license agreement for oral glp-1 receptor agonist with cspc pharmaceutical group limited

Conshohocken, pa., july 30, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl) (“madrigal”) today announced that it has entered into an exclusive global license agreement with cspc pharmaceutical group limited (hkex stock codel 1093) (“cspc”) for syh2086, a preclinical oral small molecule glucagon-like peptide-1 (glp-1) receptor agonist and orforglipron derivative. madrigal plans to initiate clinical development in the first half of 2026.
MDGL Ratings Summary
MDGL Quant Ranking